Lundbeck and Otsuka Pharmaceutical sign historic agreement
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced a development and commercialisation agreement for up to five products in the psychiatry field, including aripiprazole depot formulation and OPC-34712 from Otsuka and up to three highly innovative earlier stage projects from Lundbeck.
Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced positive preliminary results from the Phase 2 study program in which patients with elevated low-density lipoprotein cholesterol (LDL-C) were treated with REGN727/SAR236553.
Lundbeck's third quarter report 2011 - The positive momentum continues
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) reports third quarter revenue of DKK 3,975 million, an increase of 10% compared to the same quarter last year. The growth was driven by increasing revenue from key products and a milestone payment related to the launch of escitalopram in Japan.
Novartis appoints Timothy Wright, M.D. as Global Head, Development, Novartis Pharmaceuticals
- Details
- Category: Novartis
Novartis announced the appointment of Timothy Wright, M.D. as Global Head, Development, Novartis Pharmaceuticals effective immediately.
Treatment with Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits
- Details
- Category: Pfizer
Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) announced results of the second and final period of the PRESERVE trial. PRESERVE is a two-period multi-center trial in patients with moderately active rheumatoid arthritis (RA) who achieved Disease Activity Score (DAS) 28 low disease activity (LDA) or clinical remission on combination Enbrel® (etanercept) plus
New Structure of Business Operations for a Global Pharmaceutical Company
- Details
- Category: Takeda
As part of its "Transformation into a New Takeda", Takeda Pharmaceutical Company Limited ("Takeda") has implemented several strategies to realize its corporate vision of achieving "sustainable growth" by 2015 through "innovation" and "culture".
PATH, Abbott and the Abbott Fund Form Innovative Partnership to Prevent Malnutrition
- Details
- Category: Abbott
PATH, Abbott (NYSE: ABT) and the Abbott Fund announced a partnership to address malnutrition by advancing the rice fortification market in India. Currently, 200 million people suffer from hunger and malnutrition in India, more than any other country in the world.
More Pharma News ...
- ASLAN Pharmaceuticals and Bristol-Myers Squibb Enter Innovative Partnership
- Sanofi net sales up 10.1% and Business net income up 4.1% at CER
- Lilly CEO Says Appropriate Assessment of Both Benefits and Risks Critical in Regulatory Process
- Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME(TM) Drug Eluting Stent
- Pfizer Reports Third-Quarter 2011 Results
- Daiichi Sankyo Establishes New Vaccine Research Unit in Japan
- Pfizer Completes Acquisition Of Icagen